Comprehensive end-to-end services enable effective, streamlined communication with key stakeholders across all stages of drug development and commercialization
BOSTON, March 21, 2018 – PAREXEL International Corporation, the world’s leading innovator of biopharmaceutical services, today introduced PAREXEL's Medical Writing Solutions, a newly integrated, end-to-end offering that provides a wide variety of communication services needed throughout each critical stage of the drug development and commercialization process.
Biopharmaceutical companies today are increasingly in need of high quality documentation to meet product development and commercialization demands. They also need to effectively communicate with a wide range of key stakeholders including those in the scientific, regulatory and medical communities, as well as patient and payer communities. While companies often engage audiences on an isolated or separate basis, PAREXEL’s Medical Writing Solutions delivers the increased value that comes with an integrated, streamlined communications strategy across the drug development and commercialization continuum.
“As the drug development journey continues to evolve with the advancements in trial design and technology, and regulatory requirements change, it is vital that clients have access to highly-experienced medical writers who can communicate with all stakeholders in an integrated way, eliminating silos and telling a more holistic story through each stage of development and commercialization,” said Julia Cooper Vice President, Head of Global Medical Writing Solutions at PAREXEL. “Our deep cross-functional expertise enables us to optimize the medical writing process for our clients, and ultimately allows them to engage more effectively with audiences that are critical in bringing new therapies to market.”
Building upon PAREXEL’s already-available scientific, technical, medical and regulatory communications services, the Medical Writing Solutions team is made up of more than 800 highly trained experts around the globe experienced in developing high-quality documents, such as protocols, new drug applications, medical education materials and regulatory authority meeting briefing documents. Through frequent interactions with regulatory agencies, payers, medical practitioners, and patients, PAREXEL’s team ensures documents prepared provide clear, cohesive communications that are compliant with the latest regulations and guidelines.
As the latest addition to PAREXEL’s Connected Journey™ of more than 40 data-driven services, the Medical Writing Solutions offering leverages data-driven insights in its communications to drive value for clients. The offering is currently available as both functional service projects or as part of larger strategic partnerships based on their study needs. For more information visit http://www.parexel.com/medicalwriting.
About PAREXEL International
PAREXEL International Corporation is the world’s leading innovator of biopharmaceutical services. We simplify our clients’ journey of transforming scientific discoveries into new medical treatments for patients with high-quality Phase I-IV clinical research, regulatory, consulting and market access services. PAREXEL develops breakthrough innovations and solutions by leveraging its comprehensive therapeutic, technical and functional expertise, along with its industry knowledge, in more than 100 countries around the world. For more information visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners.
# # #
Tel.: +1 781-434-4772
Kathryn McMahon Arrigg, PAN Communications
Tel.: +1 617-502-4300